Basilea Pharmaceutica AG has announced a significant milestone in its partnership with Pfizer Inc. The collaboration, which covers Europe (excluding the Nordic countries), China, and 16 countries in the Asia-Pacific region, has led to impressive sales growth for Cresemba® (Isavuconazol). The continued strong performance in these regions has triggered a second milestone payment of USD 2.5 million to Basilea. This partnership aims to address the rising global demand for innovative antifungal medications, with Cresemba being particularly well-received in China. The success underscores the drug's high clinical value for patients with life-threatening infections, highlighting the joint commitment of Basilea and Pfizer to make Cresemba accessible to affected patients worldwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.